Pig tissue factor pathway inhibitor alpha fusion immunoglobulin inhibits pig tissue factor activity in human plasma moderately more efficiently than the human counterpart
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Choi, Chang-Yong | - |
dc.contributor.author | Kim, Yeon-Hui | - |
dc.contributor.author | Bae, Joonbeom | - |
dc.contributor.author | Lee, Suk Jun | - |
dc.contributor.author | Kim, Hyun Kyung | - |
dc.contributor.author | Park, Chung-Gyu | - |
dc.contributor.author | Chun, Taehoon | - |
dc.date.accessioned | 2021-09-02T23:53:21Z | - |
dc.date.available | 2021-09-02T23:53:21Z | - |
dc.date.issued | 2017-11 | - |
dc.identifier.issn | 0141-5492 | - |
dc.identifier.issn | 1573-6776 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/81789 | - |
dc.description.abstract | To determine the efficacy of soluble pig tissue factor pathway inhibitor fusion immunoglobulin (TFPI-Ig) in blocking pig to human xenogeneic blood coagulation. To generate pig TFPI-Ig or human TFPI-Ig, expression vector containing cDNA encoding pig TFPI alpha or human TFPI alpha combined with human constant Ig heavy chain region was cloned and introduced into CHO cells. After purification of pig TFPI-Ig and human TFPI-Ig, the inhibition of each recombinant protein on pig tissue factor (TF)-mediated blood coagulation was examined in human plasma. Compared to human TFPI-Ig, pig TFPI-Ig inhibited pig TF activity and thrombin generation in human plasma more efficiently at certain concentrations. Pig TFPI-Ig will be be useful as a therapeutic protein to treat pig to human xenogeneic blood coagulation. | - |
dc.format.extent | 8 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | SPRINGER | - |
dc.title | Pig tissue factor pathway inhibitor alpha fusion immunoglobulin inhibits pig tissue factor activity in human plasma moderately more efficiently than the human counterpart | - |
dc.type | Article | - |
dc.publisher.location | 네덜란드 | - |
dc.identifier.doi | 10.1007/s10529-017-2405-3 | - |
dc.identifier.scopusid | 2-s2.0-85026916923 | - |
dc.identifier.wosid | 000412733200004 | - |
dc.identifier.bibliographicCitation | BIOTECHNOLOGY LETTERS, v.39, no.11, pp 1631 - 1638 | - |
dc.citation.title | BIOTECHNOLOGY LETTERS | - |
dc.citation.volume | 39 | - |
dc.citation.number | 11 | - |
dc.citation.startPage | 1631 | - |
dc.citation.endPage | 1638 | - |
dc.type.docType | Article | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | sci | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Biotechnology & Applied Microbiology | - |
dc.relation.journalWebOfScienceCategory | Biotechnology & Applied Microbiology | - |
dc.subject.keywordPlus | COAGULATION INHIBITOR | - |
dc.subject.keywordPlus | FACTOR-XA | - |
dc.subject.keywordPlus | DEGRADATION | - |
dc.subject.keywordPlus | EXPRESSION | - |
dc.subject.keywordPlus | DOMAINS | - |
dc.subject.keywordPlus | ISLETS | - |
dc.subject.keywordAuthor | Blood coagulation | - |
dc.subject.keywordAuthor | Recombinant protein | - |
dc.subject.keywordAuthor | Tissue factor | - |
dc.subject.keywordAuthor | Tissue factor pathway inhibitor | - |
dc.subject.keywordAuthor | Xenotransplantation | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
145 Anam-ro, Seongbuk-gu, Seoul, 02841, Korea+82-2-3290-2963
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.